[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_76":77},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":16,"_18":-5,"_19":-5,"_20":21,"_22":23,"_24":25,"_26":27,"_28":27,"_29":-5,"_30":31,"_32":33,"_34":-5,"_35":36,"_37":38,"_39":-5,"_40":-5,"_41":42,"_43":-5,"_44":-5,"_45":46,"_47":48,"_49":50,"_51":52,"_53":52,"_54":-5,"_55":36,"_56":57},"id","gsrablptjucibjeshdixba2sk","revision",1,"title","6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)","originalTitle","summary","reason","source",{"_11":66,"_67":68,"_69":70,"_71":52,"_72":73,"_74":75},"links",{"_63":64,"_57":65},"publishedAt","2026-10-20T10:07:14.000Z","discoveredAt","2026-10-20T11:57:26.204Z","timelineAt","category","tags",[],"stockSymbols",[62],"score","selected",false,"channel","news","story","x","readingMode","full","author","language","body",{"_58":-5,"_57":59,"_60":-5,"_61":36},"outline",[],"relatedStories",[],"indexable",true,"markdownAvailable","group","hasTranslation","bodyLanguage","original","zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2026

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South,\nVictoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant\nfiles or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form\n40-F ☐

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”)\npublished two announcements (the “Public Notice”) to the Australian Securities Exchange on October 20, 2026 titled:

“Change of Director's Interest Notices x 4”

“Notification regarding unquoted securities - RAD”

A copy of the Public Notice is attached as an exhibit to this report\non Form 6-K.

This report on Form 6-K (including any exhibit\nhereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 and shall not be incorporated\nby reference into any registration statement or prospectus under the Securities Act of 1933, except as shall be expressly set forth by\nspecific reference in such registration statement or prospectus.

EXHIBITS

\n \n \n \n \n \n \n \n \n \n \n \n \n

Exhibit\n \n Number		Description
99.1		Change of Director's Interest Notices x 4
99.2		Notification regarding unquoted securities - RAD

SIGNATURE

Pursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto\nduly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	RADIOPHARM THERANOSTICS LIMITED

Date: October 20, 2026	By:	/s/ Amritha Sushil
		Amritha Sushil
		Company Secretary

","zhKind","complete","RADX","aihot","/items/gsrablptjucibjeshdixba2sk","https://www.sec.gov/Archives/edgar/data/1949257/000121390026110813/0001213900-26-110813-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792713600&sig=5c6d5f091d1967b7","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792713600&sig=86138d453cd8c096 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792713600&sig=e067c63cbf80f0de 96w","changelogVersion","2026-10-01T08:00"]